Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer - Clinical Lung Cancer
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Emergence of pre-existing MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping – topic of research paper in Clinical medicine. Download scholarly article PDF and
An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology | Laboratory Investigation
Identification of tumor-specific, intronic mutations in Met leading to... | Download Scientific Diagram
Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients - Journal of Thoracic Oncology
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEJM
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - Lung Cancer
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
MET Mutation Associated with Responsiveness to Crizotinib. - Abstract - Europe PMC
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
![MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/67fdcd54f931874b6e6ffa4ffca44de1124ea7f0/5-Figure1-1.png "MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar")
MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar
Diagnosis and Discussion -- Case 1068
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEJM
Heymach Discusses MET Exon 14 Skipping Mutations in NSCLC
Lung cancer with MET exon 14 skipping mutation | LCTT
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer - Lung Cancer
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer
Diagnosis and Discussion -- Case 1068
Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation - Clinical Lung Cancer
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers - Lung Cancer
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
![PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/df73d74a72129de1592255fc0a74db3d4b45eef3/2-Figure1-1.png "PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar")